The Latest
-
Facebook may be headed to the ‘graveyard of dinosaurs’: former Unilever CEO
-
Here’s Why We’re Not Too Worried About Microbot Medical’s (NASDAQ:MBOT) Cash Burn Situation
-
Amgen defeats Novartis appeal over arthritis drug Enbrel’s patents
-
Virus Shot From Pfizer, BioNtech Shows Promise in Early Test